Related Experiment Video

Updated: Aug 7, 2026

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach
10:01

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach

Published on: June 23, 2026

Computational insight into anti-mutagenic properties of CYP1A flavonoid ligands

Rute da Fonseca1, Michele Marini, André Melo

  • 1Departamento de Química, Faculdade de Ciencias, Universidade do Porto, Rua do Campo Alegre, 687, 4169-007 Porto, Portugal.

Medicinal Chemistry (Shariqah (United Arab Emirates))
|June 23, 2006
PubMed

Insights

Flavonoids may inhibit Cytochrome P450 1A (CYP1A) enzymes, which activate carcinogens in cooked meat. This study explores their interaction using computational methods, offering alternatives to traditional QSAR analysis for understanding protein-inhibitor relationships.

Area of Science:

  • Biochemistry
  • Computational Chemistry
  • Pharmacology

Background:

  • Cytochrome P450 1A (CYP1A) enzymes metabolize heterocyclic amines in cooked red meat into carcinogens.
  • Flavonoids are known for their anti-cancer properties and potential interactions with CYP1A enzymes, particularly CYP1A2.

Purpose of the Study:

  • To investigate the interaction between flavonoids and Cytochrome P450 1A2 (CYP1A2).
  • To explore computational methods as alternatives to quantitative structure-activity relationship (QSAR) analysis for studying protein-inhibitor interactions.

Main Methods:

  • Utilized quantum mechanics (QM) for detailed electronic structure calculations.
  • Employed molecular mechanics (MM) for larger-scale simulations of protein-inhibitor interactions.
  • Proposed a complementary approach combining QM and MM to provide comprehensive insights.

Main Results:

  • The study proposes QM and MM as viable alternatives for analyzing protein-inhibitor interactions when experimental data is limited.
  • These computational methods offer a way to understand how flavonoids interact with CYP1A enzymes.

Conclusions:

  • Computational approaches, including QM and MM, can effectively study protein-inhibitor interactions, complementing experimental methods.
  • This research provides a foundation for further investigation into flavonoids as potential modulators of CYP1A activity and cancer risk.

More Related Videos

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 406:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

Related Concept Videos

Ligand Binding and Linkage00:49

Ligand Binding and Linkage

Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked.  In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence the...
The Equilibrium Binding Constant and Binding Strength02:18

The Equilibrium Binding Constant and Binding Strength

The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Ligand Binding Sites02:40

Ligand Binding Sites

Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...